---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-163398"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:51:35.362024+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio raises $12.6M via equity sales to Armistice & Gilead; cash runway into Q1 2026

## Summary
- Gross proceeds of $12.6M from sale of common stock and warrants to Armistice Capital and Gilead.
- Armistice bought 634,500 shares + warrants; Gilead bought 179,500 shares + warrants at $15.46/combined unit.
- Warrants exercisable at $17.00/share, expire June 18, 2029; proceeds for general corporate purposes.
- Cash runway extended into Q1 2026; key data readouts: ABI-5366 Phase 1a in Q3 2024, Phase 1b in H1 2025.
- Agreement amendments with Gilead extend timeline for potential ownership increase up to 29.9%.

## SEC filing metadata
- accession: 0001193125-24-163398
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312524163398/0001193125-24-163398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312524163398/d852840d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-163398
- JSON: https://secwatch.observer/filing/0001193125-24-163398.json
- Plain text: https://secwatch.observer/filing/0001193125-24-163398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.